Logo

Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

Share this

Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

Shots:

  • The P-II ZUMA-5 trial assessing Yescarta in 146 patients aged ≥18rs. with r/r iNHL include FL- prior treated with at least 2L of systemic therapy
  • Results: 94% of patients achieved a response @18mos.- & 2EPs of mPFS and OS were not yet reached. In a weighted analysis- the results compared with ZUMA-5 patients vs SCHOLAR-5 patients- therapy showed superior OS & PFS over currently available treatments
  • Patients achieved a response (94% vs 50%) @median follow-up of 26.2 mos.- reduction in risk of disease progression (58% vs 70%)- relapse or death vs current therapies in a control cohort- m-PFS & OS (12.7 & 59.8 mos.) in a control cohort- respectively

  | Ref: Business Wire | Image: Business Wire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions